Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease-Reference-Cited by-同舟云学术

Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease

Published:2017-01-16 Issue:8 Volume:58 Page:1989-1992
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kieslich Anna¹^ORCID,Ruf Peter²,Lindhofer Horst²,Buhmann Raynold³,Eggert Angelika¹,Hundsdoerfer Patrick¹

Affiliation:

1. Department of Pediatrics, Division of Oncology and Hematology, Charité University Medicine, Berlin, Germany;

2. TRION Research GmbH, Munich, Germany;

3. Department of Medicine III and Transfusion Medicine, University Hospital Grosshadern, LMU, Munich, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1272687

Reference17 articles.

1. Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents

2. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia

3. Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation

4. Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients

5. CNS or Bone Marrow Involvement As Risk Factors for Poor Survival in Post-Transplantation Lymphoproliferative Disorders in Children After Solid Organ Transplantation

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma;Journal for ImmunoTherapy of Cancer;2021-07

2. Bispecific antibodies in acute lymphoblastic leukemia therapy;Expert Review of Hematology;2020-11-01

3. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies;Frontiers in Immunology;2020-05-07

4. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?;Current Oncology Reports;2019-02

5. T lymphocytes as therapeutic arsenal for patients with hematological malignancies;Current Opinion in Oncology;2018-11